NEW YORK--(BUSINESS WIRE)--Six major strategies – R&D restructuring, revisiting the FDA approval process, personalized medicine, private exchanges for early-stage funding, contract R&D and new uses for gene and stem-cell therapy – will emerge as integral to the future success of the biopharma industry, according to a pivotal report that evaluated the most important issues facing the biopharma industry. BlissHealth, a full-service healthcare, biotech and pharma public relations and marketing communications practice, partnered with Wiktive Intelligence Markets, a market research firm, to explore the opinions of an expert panel of industry leaders in order to gather critical market opinions.
